IDH2 and acute myeloid leukemia: Furthermore, enasidenib is an IDH2 mutant inhibitor that can increase the sensitivity to venetoclax; this sensitizing effect was observed both in vitro and in human AML xenograft models and seemed to depend on whether the leukemic cells differentiated (i.e., decreased c-kit/CD117 and increased granulocytic marker GR-1) in response to the enasidenib treatment [220].